Data as of Oct 21
| +0.0088 / +0.90%|
The 1 analysts offering 12-month price forecasts for Provectus Biopharmaceuticals Inc have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +253.96% increase from the last price of 0.99.
The current consensus among 1 polled investment analysts is to Buy stock in Provectus Biopharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.